Cipla to Market Eli Lilly’s Weight Loss Drug as Yurpeak in India
In a significant development for India’s pharmaceutical market, Eli Lilly has partnered with Cipla to sell its blockbuster weight-loss drug under the new brand name Yurpeak. The agreement, announced on October 23, 2025, will make this highly effective treatment more accessible to Indian patients.
Key Takeaways
- Cipla will market Eli Lilly’s weight-loss drug as ‘Yurpeak’ in India.
- The drug will be available as a once-weekly pre-filled injector pen.
- It will be priced the same as Lilly’s existing Mounjaro product.
- Six different dose strengths will be offered to personalize treatment.
Partnership Details and Product Features
Under the manufacturing and marketing agreement, Eli Lilly will produce the drug while Cipla handles its commercialization under the Yurpeak brand. The medication will be available as a once-weekly pre-filled injector pen, identical to Lilly’s Mounjaro Kwikpen, enabling healthcare providers to create personalized treatment plans for patients.
The drug will be offered in six dosage options: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, with pricing matching that of Mounjaro. This strategic partnership follows Lilly’s successful introduction of Mounjaro in India for diabetes and obesity treatment earlier this year.
Market Context and Performance
Eli Lilly began selling Mounjaro in India in late March 2025, initially offering 2.5 mg and 5 mg vials for diabetes and obesity treatment. The company received approval from India’s drug regulator for the Kwikpen device in June, and the drug’s sales more than doubled within months of its launch, indicating strong market demand.
How Tirzepatide Works
The active ingredient, tirzepatide, belongs to the GLP-1 receptor agonist class of therapies. These medications work by controlling blood sugar levels and slowing digestion, which helps people feel fuller for longer periods, supporting weight management efforts.
